A “significant number of patients” could see a cure for multiple myeloma within the next two decades, one expert told ...

Johnson & Johnson (NYSE:JNJ) received FDA Fast Track designation for nipocalimab as a potential treatment for systemic lupus erythematosus, supported by positive Phase 2 data and the start of a Phase ...

Zymeworks (NASDAQ:ZYME) executives used the company’s fourth-quarter 2025 results call to highlight updated clinical data for ...

Expansion Led by Apple, Aligned Data Centers, AWS, CyrusOne, DataBank, and Digital Realty Lithium-ion batteries, with ...

As I look back on the past year, it is clear that 2025 was one of the most significant and value-creating years in Halozyme ...

Johnson Controls International Plc sees its adjusted earnings per share rising at the fastest pace in a decade after strong quarterly order growth. The HVAC company raised its adjusted EPS outlook for ...

Nvidia's next-generation AI infrastructure operates in a way that could potentially drive demand for Johnson Controls' products. Data centers' infrastructure is not Johnson Controls' core business, ...

The "Biological Therapies for Cancer: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

Add Yahoo as a preferred source to see more of our stories on Google. House Speaker Mike Johnson (R-LA) insisted on Wednesday that he had “not lost control” of the House after members of his party ...

CORK, Ireland—Johnson Controls delivered robust financial results for fiscal year 2025 while laying out the foundation for a transformation that blends operational discipline with cutting-edge ...

Bristol Myers Squibb and Johnson & Johnson have stopped a phase 3 anticoagulant trial early for futility, closing off one avenue to market for a molecule tipped to generate multibillion-dollar sales.